Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: O/S Issue

Re: O/S Issue

in response to by
posted on Jul 20, 2007 11:20AM

And here is where I have another "agree to disagree" position with many on this board.

ANY acquisition would represent RISK, IMO.  PTSC is already considered a very risky proposition by many/the market in general (though I obviously do not share that opinion, as I consider the risk very minimal in light of the Markman result).  So adding a greater perception of risk on top of the existing perceived risk would be a bad move, IMO.  Could you absolutely assure positive earnings from the newly acquired company - significant profit (like orders of magnitude over the revenues from simple interest off the monies in the coffers)?  How much would such an entity cost?

While I really like the Holocom deal (small cost with minimal risk or exposure going forward), I believe the company is being properly prudent in holding off on a major acquisition or merger.  Wait until the risk in the current litiagation is eliminated, then assume new risk - hopefully with a ton of cash to back up the proposition.

JMHO,

SGE

Share
New Message
Please login to post a reply